Biosimilars | Specialty

The OncLive Biosimilars condition center page is a comprehensive resource for clinical news and expert insights on currently available and investigational biosimilars for reference drugs such as trastuzumab, rituximab, bevacizumab, and more. This page features news articles, interviews in written and video format, and podcasts that focus on updates with biosimilars and ongoing research with these types of agents.

Dr. Untch on the Expanding Use of Biosimilars

October 9th 2019

Michael Untch, MD, PhD, discusses the widespread use of biosimilars in Europe.

Trastuzumab Biosimilar May Alleviate Financial Toxicity in HER2+ Breast Cancer

October 2nd 2019

Chen Fu, MD, discusses the data supporting the use of CT-P6 in HER2-positive breast cancer, the benefits to bringing more biosimilars to the market, and the future that these products have in oncology.

Dr. Yardley on Integrating Biosimilars Into Breast Cancer Treatment

October 2nd 2019

Denise Yardley, MD, discusses the impact of biosimilars on breast cancer treatment.

Dr. Lyman on G-CSF Biosimilars and Potential Impact on the Market

October 1st 2019

Gary H. Lyman, MD, MPH, discusses granulocyte colony-stimulating factor biosimilars and their impact on the market.

Dr. McBride on Biosimilar Rituximab

September 27th 2019

Ali McBride, PharmD, MS, BCOP, discusses the oncology community’s reaction to biosimilars for rituximab (Rituxan).

Dr. Lyman on Challenges with Biosimilar Policies

September 25th 2019

Gary H. Lyman, MD, MPH, discusses challenges in biosimilar policies.

Regulatory Decisions, New Data Propel Progress With Biosimilars in Oncology

September 21st 2019

The uptick of biosimilars has led to a surge of new data and regulatory decisions in recent years, with a focus on similarity between biosimilars and their reference products while reducing healthcare costs. This week, data on subcutaneous formulations of one biosimilar and long-term experience with another were provided, as well as an authorization of a trastuzumab (Herceptin) biosimilar in Canada.

Dr. Welslau on REFLECT Interim Safety Analysis in DLBCL

September 20th 2019

Manfred Welslau, MD, discusses the first interim safety analysis in treatment-naïve, CD20-positive diffuse large B-cell lymphoma following the approval of Rixathon, a Sandoz biosimilar for rituximab.

Dr. Welslau on the Rationale for the REFLECT Trial in DLBCL

September 19th 2019

Manfred Welslau, MD, Internal Medicine, Hematology and Oncology, Onkologie Aschaffenburg, discusses the rationale for the REFLECT trial in diffuse large B-cell lymphoma.

Dr. Lyman on Rituximab Biosimilars in Non-Hodgkin Lymphoma

September 19th 2019

Gary H. Lyman, MD, MPH, senior lead, Health Care Quality and Policy, Hutchinson Institute for Cancer Outcomes Research, member, Cancer Prevention Program, Public Health Services Division, and member, Clinical Research Division, Fred Hutchinson Cancer Research Center, discusses the use of rituximab (Rituxan) biosimilars in the treatment of patients with non-Hodgkin lymphoma (NHL).

Lyman Shares Blueprint for Boosting Biosimilar Uptake in Oncology

September 16th 2019

Gary H. Lyman, MD, MPH, discusses the current parameters used to develop a biosimilar, the impact these products have had in the treatment and supportive care settings, and ongoing initiatives to address remaining challenges.

Dr. Schmid on Evaluating Biosimilars in Oncology

September 13th 2019

Peter Schmid, MD, PhD, lead at the Centre for Experimental Cancer Medicine, Barts Cancer Institute, discusses the evaluation of biosimilars in oncology.

Dr. De Censi on the Hope for Biosimilars in the United States

September 13th 2019

Andrea De Censi, MD, director of the medical oncology unit at the National Hospital E.O. Ospedali Galliera–SC Oncologia Medica in Genoa, Italy, discusses the hope for biosimilars in the United States.

Dr. Lyman on Educational Initiatives Regarding the Use of Biosimilars in Oncology

September 12th 2019

Gary H. Lyman, MD, MPH, senior lead, Health Care Quality and Policy, Hutchinson Institute for Cancer Outcomes Research, member, Cancer Prevention Program, Public Health Services Division, and member, Clinical Research Division, Fred Hutchinson Cancer Research Center, discusses educational initiatives regarding the use of biosimilars in oncology.

Dr. Hershman on the Equivalency of Biosimilars and Biologics

September 6th 2019

Dawn L. Hershman, MD, MS, professor of Medicine and Epidemiology, Columbia University Medical Center, leader of the breast cancer program at NewYork-Presbyterian/Columbia University Irving Medical Center, discusses the equivalency of biosimilars and biologics.

Efforts Ongoing to Move Biosimilars Into Mainstream Cancer Care

September 6th 2019

Lee S. Schwartzberg, MD, discusses the mission of OneOncology as well as the work that is being done to bring biosimilars to the market.

Signs Point to Better Market Conditions for Biosimilars

September 5th 2019

Even though many challenges must be overcome before widespread adoption can occur, there is still much promise on the horizon for biosimilars.

Dr. Kolberg on Collecting Real-World Biosimilar Trastuzumab Data in Breast Cancer

September 4th 2019

Hans-Christian Kolberg, MD, discusses collecting real-world data for biosimilars, specifically the trastuzumab biosimilar ABP 980 for breast cancer.

Dr. Welslau on Financial Savings of Biosimilar Rituximab in DLBCL

August 30th 2019

Manfred Welslau, MD, discusses financial savings of using a rituximab biosimilar for patients with previously untreated CD20-positive diffuse large B-cell lymphoma.

Efficacy, Education, and Cost-Effectiveness Mark Latest Biosimilar Developments

August 30th 2019

A cluster of clinical news in biosimilars has been announced over the last few days, with pooled data sets against reference products, an expected launch of a novel study, and a cost efficiency analysis.